Ra Capital Management as of June 30, 2014
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 26 positions in its portfolio as reported in the June 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Achillion Pharmaceuticals | 19.5 | $193M | 26M | 7.57 | |
| Sangamo Biosciences (SGMO) | 13.6 | $134M | 8.8M | 15.27 | |
| ACADIA Pharmaceuticals (ACAD) | 12.0 | $119M | 5.3M | 22.59 | |
| Dyax | 9.7 | $96M | 10M | 9.60 | |
| Enanta Pharmaceuticals (ENTA) | 6.7 | $66M | 1.5M | 43.07 | |
| Dicerna Pharmaceuticals | 5.5 | $55M | 2.4M | 22.57 | |
| Versartis | 5.1 | $50M | 1.2M | 41.65 | |
| BioCryst Pharmaceuticals (BCRX) | 4.1 | $41M | 3.2M | 12.75 | |
| Sunesis Pharmaceuticals | 3.2 | $32M | 4.9M | 6.52 | |
| Novavax | 3.1 | $31M | 6.7M | 4.62 | |
| Dynavax Technologies Corporation | 2.3 | $23M | 14M | 1.60 | |
| Ophthotech | 2.3 | $22M | 528k | 42.31 | |
| Repros Therapeutics | 2.1 | $21M | 1.2M | 17.30 | |
| Bluebird Bio (BLUE) | 2.0 | $19M | 503k | 38.57 | |
| Therapeuticsmd | 1.9 | $19M | 4.3M | 4.42 | |
| Akebia Therapeutics (AKBA) | 1.7 | $17M | 597k | 27.79 | |
| Xencor (XNCR) | 1.2 | $12M | 1.0M | 11.62 | |
| pSivida | 1.1 | $11M | 2.6M | 4.34 | |
| Arrowhead Research | 0.9 | $8.6M | 604k | 14.31 | |
| Scynexis | 0.7 | $6.7M | 840k | 8.02 | |
| Alimera Sciences | 0.4 | $4.0M | 667k | 5.98 | |
| Ocera Therapeutics | 0.4 | $3.7M | 491k | 7.64 | |
| Immunomedics | 0.4 | $3.7M | 1.0M | 3.65 | |
| Oxygenbiotherapeutics Inccom Par | 0.1 | $1.3M | 315k | 4.08 | |
| Neurocrine Biosciences (NBIX) | 0.1 | $1.0M | 69k | 14.83 | |
| Prana Biotechnology | 0.0 | $227k | 100k | 2.27 |
